Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company
specializing in highly effective, non-invasive, minimally-invasive
and cost-effective treatments for oncological and non-oncological
conditions, has installed the first SRT-100™ System in Ireland at
Dublin’s Beacon Hospital. The system will provide a highly
efficacious and non-invasive solution to treat the growing numbers
of non-melanoma skin cancer patients in Ireland, which is estimated
by the Irish Cancer Society to number 12,000 annually and growing.
Siobhra O’Sullivan, M.D., lead radiation
oncologist at Beacon Hospital said, “We are delighted to announce
expansion of our radiotherapy services at Beacon Hospital, Dublin,
with the delivery of the Sensus SRT-100. This new unit allows
us to provide non-surgical superficial radiotherapy treatments for
patients with non-melanoma skin cancers, such as squamous cell
carcinoma and basal cell carcinoma, and will also be used in the
management of keloid scars.
“At Beacon Hospital, our skin cancer services
are provided by a multidisciplinary team of radiation oncologists,
plastic surgeons, dermatologists, and medical oncologists, to
provide patients we serve with the most advanced and proven
treatments. The SRT-100 is an exciting addition to our hospital,
and we are delighted to be the first facility in Ireland with this
unit.”
Dr. O’Sullivan added, “We would like to thank
the Sensus team for a seamless install, which resulted in minimal
disruption to our busy department, and we look forward to treating
our first patients very soon!”
Commenting on the sale, Joe Sardano, chairman
and chief executive officer of Sensus Healthcare, said, “We are
thrilled to generate our first sale of an SRT System in Ireland and
to a leading, technologically savvy facility such as Beacon
Hospital. Beacon will serve as an example to the Irish
dermato-oncology community of innovation in patient care. We
expect that this system will be the first of many placed not only
in Ireland, but in the United Kingdom as well.”
About Beacon Hospital
Located in Sandyford, South Dublin, Beacon
Hospital is one of the most technologically advanced private
hospitals in all of Europe.
With 181 inpatients beds, 70 day-case beds,
eight operating theatres, two cath labs, four endoscopy suites,
over 1600 healthcare professionals and upwards of 300 consultants,
Beacon Hospital operates as a full-service acute hospital.
Departments include, but are not limited to; Cancer Care,
Cardiology, Cardiothoracic Surgery, Dermatology, Emergency
Medicine, Endocrinology, Endoscopy, ENT, General Medicine and
Surgery, Intensive Care, Neurology & Neurosurgery,
Orthopaedics, Physiotherapy, Paediatric Care (medical &
surgical), Plastic Surgery, Radiology, Rheumatology, Sports
Medicine, Urology, Vascular Services, Women’s Health and
Men’s Health and more.
Beacon Hospital treated over 207,000 patients
last year across all areas of medicine and surgery. Click here to
read more about Beacon Hospital’s Department’s and Services.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device
company specializing in highly effective, non-invasive, minimally
invasive and cost-effective treatments for both oncological and
non-oncological conditions. Sensus offers its proprietary
low-energy X-ray technology known as superficial radiation therapy
(SRT), which is the culmination of more than a decade of research
and development, to treat non-melanoma skin cancers and keloids
with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its
portfolio of innovative medical device products, including its
needleless TransDermal Infusion System™, Sensus provides
revolutionary treatment options to enhance the quality of life of
patients around the world.
For more information, visit
www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are,
or may be deemed, ''forward-looking statements.'' In some cases,
these statements can be identified by the use of forward-looking
terminology such as "believes," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "will,"
"should," “approximately,” "potential" or negative or other
variations of those terms or comparable terminology, although not
all forward-looking statements contain these words.
Forward-looking statements involve risks and
uncertainties because they relate to events, developments, and
circumstances relating to Sensus, our industry, and/or general
economic or other conditions that may or may not occur in the
future or may occur on longer or shorter timelines or to a greater
or lesser degree than anticipated. Although we believe that we have
a reasonable basis for each forward-looking statement contained in
this press release, forward-looking statements are not guarantees
of future performance, and our actual results of operations,
financial condition and liquidity, and the development of the
industry in which we operate may differ materially from the forward
looking statements contained in this press release, as a result of
the following factors, among others: our ability to return to
profitability; our ability to sell the number of SRT units we
anticipate for the balance of 2023; the possibility that
inflationary pressures continue to impact our sales; our ability to
obtain and maintain the intellectual property needed to adequately
protect our products, and our ability to avoid infringing or
otherwise violating the intellectual property rights of third
parties; the level and availability of government and/or third
party payor reimbursement for clinical procedures using our
products, and the willingness of healthcare providers to purchase
our products if the level of reimbursement declines; the regulatory
requirements applicable to us and our competitors; our ability to
efficiently manage our manufacturing processes and costs; the risks
arising from doing business in China and other foreign countries;
legislation, regulation, or other governmental action that affects
our products, taxes, international trade regulation, or other
aspects of our business; concentration of our customers in the U.S.
and China, including the concentration of sales to one particular
customer in the U.S.; and other risks described from time to time
in our filings with the Securities and Exchange Commission,
including our Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q.
To date, we do not expect that the Russian
invasion of Ukraine and global geopolitical uncertainty have not
had any particular impact on our business, but we continue to
monitor developments and will address them in future disclosures,
if applicable.
In addition, even if future events,
developments, and circumstances are consistent with the
forward-looking statements contained in this press release, they
may not be predictive of results or developments in future periods.
Any forward-looking statements that we make in this press release
speak only as of the date of such statement, and we undertake no
obligation to update such statements to reflect events or
circumstances after the date of this press release, except as may
be required by applicable law. You should read carefully our
"Introductory Note Regarding Forward-Looking Information" and the
factors described in the "Risk Factors" section of our periodic
reports filed with the Securities and Exchange Commission to better
understand the risks and uncertainties inherent in our
business.
Contact: LHA Investor
RelationsKim Sutton Golodetz212-838-3777kgolodetz@lhai.com
# # #
Sensus Healthcare (NASDAQ:SRTS)
Historical Stock Chart
From Apr 2024 to May 2024
Sensus Healthcare (NASDAQ:SRTS)
Historical Stock Chart
From May 2023 to May 2024